| US709844A (en) | 1902-05-28 | 1902-09-23 | Darwin E Wright | Locking device for filing-receptacles or the like. |
| US4361549A (en) | 1979-04-26 | 1982-11-30 | Ortho Pharmaceutical Corporation | Complement-fixing monoclonal antibody to human T cells, and methods of preparing same |
| US4683202A (en) | 1985-03-28 | 1987-07-28 | Cetus Corporation | Process for amplifying nucleic acid sequences |
| US4683202B1 (fr) | 1985-03-28 | 1990-11-27 | Cetus Corp | |
| US5585362A (en) | 1989-08-22 | 1996-12-17 | The Regents Of The University Of Michigan | Adenovirus vectors for gene therapy |
| US5871732A (en) | 1990-11-27 | 1999-02-16 | Biogen, Inc. | Anti-CD4 antibody homologs useful in prophylaxis and treatment of AIDS, ARC and HIV infection |
| US7338658B2 (en) | 1991-07-25 | 2008-03-04 | Biogen Idec Inc. | Recombinant anti-CD4 antibodies for human therapy |
| US5538725A (en) | 1991-10-18 | 1996-07-23 | Hoffman-La Roche Inc. | Method of inhibiting metastasis by anti-α6-integrin-antibodies |
| EP0656946A1 (fr) | 1992-08-21 | 1995-06-14 | Vrije Universiteit Brussel | Immunoglobulines exemptes de chaines legeres |
| US5350674A (en) | 1992-09-04 | 1994-09-27 | Becton, Dickinson And Company | Intrinsic factor - horse peroxidase conjugates and a method for increasing the stability thereof |
| US6132992A (en) | 1993-02-01 | 2000-10-17 | Bristol-Myers Squibb Co. | Expression vectors encoding bispecific fusion proteins and methods of producing biologically active bispecific fusion proteins in a mammalian cell |
| WO1996034103A1 (fr) | 1995-04-25 | 1996-10-31 | Vrije Universiteit Brussel | Fragments variables d'immunoglobulines et leur utilisation dans un but therapeutique ou veterinaire |
| US6013516A (en) | 1995-10-06 | 2000-01-11 | The Salk Institute For Biological Studies | Vector and method of use for nucleic acid delivery to non-dividing cells |
| US6162427A (en) | 1995-12-20 | 2000-12-19 | Roche Diagnostics Gmbh | Combination of G-CSF with a chemotherapeutic agent for stem cell mobilization |
| US5928906A (en) | 1996-05-09 | 1999-07-27 | Sequenom, Inc. | Process for direct sequencing during template amplification |
| US7722873B2 (en) | 1996-10-10 | 2010-05-25 | Genpharm International, Inc. | Heterologous antibodies which bind human CD4 |
| WO1998017815A1 (fr) | 1996-10-17 | 1998-04-30 | Oxford Biomedica (Uk) Limited | Vecteurs retroviraux |
| US7541034B1 (en) | 1997-03-20 | 2009-06-02 | The United States Of America As Represented By The Department Of Health And Human Services | Recombinant antibodies and immunoconjugates targeted to CD-22 bearing cells and tumors |
| DE19727813C1 (de) | 1997-06-30 | 1998-06-18 | Univ Eberhard Karls | Antikörper 67D2 |
| DE19727815C1 (de) | 1997-06-30 | 1998-06-18 | Univ Eberhard Karls | Antikörper N6B6 |
| US6416997B1 (en) | 1997-09-18 | 2002-07-09 | The Trustees Of The University Of Pennsylvania | Receptor-binding pocket mutants of influenza a virus hemagglutinin for use in targeted gene delivery |
| WO1999015683A1 (fr) | 1997-09-25 | 1999-04-01 | Oxford Biomedica (Uk) Limited | Vecteurs retroviraux comprenant un site donneur d'epissage fonctionnel et un site accepteur d'epissage fonctionnel |
| US5994136A (en) | 1997-12-12 | 1999-11-30 | Cell Genesys, Inc. | Method and means for producing high titer, safe, recombinant lentivirus vectors |
| WO1999032646A1 (fr) | 1997-12-22 | 1999-07-01 | Oxford Biomedica (Uk) Limited | Vecteurs retroviraux bases sur le virus d'anemie infectieuse equine |
| WO1999041397A1 (fr) | 1998-02-17 | 1999-08-19 | Oxford Biomedica (Uk) Limited | Vecteurs antiviraux |
| US6682907B1 (en) | 1998-04-24 | 2004-01-27 | Institut Pasteur | Use of triplex structure DNA in transferring nucleotide sequences |
| WO2000024884A2 (fr) | 1998-10-27 | 2000-05-04 | Unilever Plc | Proteines de fixation d'antigene |
| WO2001079518A2 (fr) | 2000-04-19 | 2001-10-25 | Oxford Biomedica (Uk) Limited | Procede |
| WO2002102853A2 (fr) | 2001-06-14 | 2002-12-27 | Isis Innovation Limited | Anticorps trx1 et utilisations associees |
| US7355012B2 (en) | 2001-09-26 | 2008-04-08 | United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-CD22 antibodies with increased affinity to CD22-expressing leukemia cells |
| US20030147809A1 (en) | 2001-12-28 | 2003-08-07 | Jean Gudas | Antibodies against the MUC18 antigen |
| WO2003057006A2 (fr) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Utilisation d'anticorps diriges contre l'antigene muc18 |
| US20040115205A1 (en) | 2001-12-28 | 2004-06-17 | Menashe Bar-Eli | Use of antibodies against the MUC18 antigen |
| US20060246077A1 (en) | 2001-12-28 | 2006-11-02 | Menashe Bar-Eli | Use of antibodies against the MUC18 antigen |
| US7067131B2 (en) | 2001-12-28 | 2006-06-27 | Abgenix, Inc. | Methods for using anti-MUC18 antibodies |
| WO2003057838A2 (fr) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Anticorps contre l'antigene muc18 |
| US6924360B2 (en) | 2001-12-28 | 2005-08-02 | Abgenix, Inc. | Antibodies against the MUC18 antigen |
| WO2003057837A2 (fr) | 2001-12-28 | 2003-07-17 | Abgenix, Inc. | Procedes d'utilisation d'anticorps anti-muc18 |
| US20040028687A1 (en) | 2002-01-15 | 2004-02-12 | Waelti Ernst Rudolf | Methods and compositions for the targeted delivery of therapeutic substances to specific cells and tissues |
| US20040009604A1 (en) | 2002-03-27 | 2004-01-15 | Xiaoliu Zhang | Potent oncolytic herpes simplex virus for cancer therapy |
| US7329807B2 (en) | 2002-11-21 | 2008-02-12 | Pevion Biotech Ltd. | High-efficiency fusogenic vesicles, methods of producing them, and pharmaceutical compositions containing them |
| WO2004067554A2 (fr) | 2003-01-29 | 2004-08-12 | Tolerrx, Inc. | Compositions et procedes d'induction de tolerance d'un mammifere a un antigene |
| WO2004083247A1 (fr) | 2003-03-21 | 2004-09-30 | Biotest Ag | Anticorps humanise anti-cd4 ayant des proprietes immunosuppressives |
| WO2005014023A1 (fr) | 2003-07-29 | 2005-02-17 | Dompe' Pha.R.Ma S.P.A. | Combinaison pharmaceutique de g-csf et plgf convenant a la mobilisation des cellules souches du sang |
| US20050186182A1 (en) | 2003-11-10 | 2005-08-25 | Theresa Deisher | Methods of using G-CSF mobilized C-Kit+ cells in the production of embryoid body-like cell clusters for tissue repair and in the treatment of cardiac myopathy |
| US7982011B2 (en) | 2003-11-25 | 2011-07-19 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Mutated anti-cd22 antibodies and immunoconjugates |
| WO2006002438A2 (fr) | 2004-06-03 | 2006-01-05 | Medarex, Inc. | Anticorps humains monoclonaux anti-recepteur gamma (cd64) de la region fc |
| US7728114B2 (en) | 2004-06-03 | 2010-06-01 | Novimmune S.A. | Anti-CD3 antibodies and methods of use thereof |
| WO2005118635A2 (fr) | 2004-06-03 | 2005-12-15 | Novimmune S.A. | Anticorps anti-cd3 et leurs methodes d'utilisation |
| WO2006027202A1 (fr) | 2004-09-06 | 2006-03-16 | Unite De Recherche En Biotherapie Et Oncologie (Rubio) | Generation d'hybrides de cellules a parents multiples |
| US7939057B2 (en) | 2006-01-25 | 2011-05-10 | Mount Sinai School Of Medicine | Methods and compositions for modulating the mobilization of stem cells |
| US20090202622A1 (en) | 2006-03-03 | 2009-08-13 | Mymetics Corporation | Virosome-like vesicles comprising gp41-derived antigens |
| WO2007109052A2 (fr) | 2006-03-16 | 2007-09-27 | Genentech, Inc. | procedes de traitement du lupus au moyen d'anticorps cd4 |
| WO2008134046A1 (fr) | 2007-04-27 | 2008-11-06 | Genentech, Inc. | Anticorps anti-cd4 puissants, stables et non immunosuppresseurs |
| US8722858B2 (en) | 2007-06-25 | 2014-05-13 | Chugai Seiyaku Kabushiki Kaisha | Anti-Prominin-1 antibody having ADCC activity or CDC activity |
| WO2009001840A1 (fr) | 2007-06-25 | 2008-12-31 | Forerunner Pharma Research Co., Ltd. | Anticorps anti-prominine-1 à activité adcc ou activité cdc |
| WO2009079922A1 (fr) | 2007-12-13 | 2009-07-02 | Shanghai Guojian Bio-Tech Institute | Anticorps monoclonal anti-cd34 humanisé, sa préparation et ses utilisations |
| US20100311955A1 (en) | 2007-12-13 | 2010-12-09 | Shanhai Guojian Bio-Tech Institute | Humanized anti-human cd34 antibody, the preparation method and uses thereof |
| US20130143238A1 (en) | 2008-02-21 | 2013-06-06 | Baxter Healthcare S.A. | Procedure for the generation of a high producer cell line for the expression of a recombinant anti-cd34 antibody |
| US8399249B2 (en) | 2008-02-21 | 2013-03-19 | Baxter International Inc. | Procedure for the generation of a high producer cell line for the expression of a recombinant anti-CD34 antibody |
| US20090221003A1 (en) | 2008-02-21 | 2009-09-03 | Baxter International Inc. | Procedure for the generation of a high producer cell line for the expression of a recombinant anti-cd34 antibody |
| US8268592B2 (en) | 2008-07-17 | 2012-09-18 | Kyowa Hakko Kirin Co., Ltd | Anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| US8945870B2 (en) | 2008-07-17 | 2015-02-03 | Kyowa Hakko Kirin Co., Ltd | DNA encoding an anti-system ASC amino acid transporter 2 (ASCT2) antibody |
| US20100196398A1 (en) | 2008-09-19 | 2010-08-05 | Medimmune Llc | Targeted binding agents directed to cd105 and uses thereof |
| WO2010032059A2 (fr) | 2008-09-19 | 2010-03-25 | Medimmune Llc | Agents de liaison ciblés dirigés sur cd105 et leurs utilisations |
| US20100098692A1 (en) | 2008-10-01 | 2010-04-22 | Tracon Pharmaceuticals, Inc., A Delaware Corporation | Humanized Endoglin Antibodies |
| WO2010039873A2 (fr) | 2008-10-01 | 2010-04-08 | Tracon Pharmaceuticals, Inc. | Anticorps humanisés anti-endogline |
| US9005963B2 (en) | 2008-10-14 | 2015-04-14 | Ablynx N.V. | Amino acid sequences directed against cellular receptors for viruses and bacteria |
| WO2010051335A1 (fr) | 2008-10-31 | 2010-05-06 | Amgen Inc. | Matériels et procédés associés à la mobilisation de cellules souches par le facteur de croissance hématopoïétique g-csf polypégylé |
| US20110301227A1 (en) | 2008-12-10 | 2011-12-08 | Jean-Francois Beaulieu | Proliferation-associated modulation of the splicing of the integrin alpha 6 isoforms |
| WO2010074266A1 (fr) | 2008-12-26 | 2010-07-01 | 協和発酵キリン株式会社 | Anticorps anti-cd4 |
| US8399621B2 (en) | 2008-12-26 | 2013-03-19 | Kyowa Hakko Kirin Co., Ltd | Anti-CD4 antibody |
| WO2010104949A2 (fr) | 2009-03-10 | 2010-09-16 | Biogen Idec Ma Inc. | Anticorps anti-bcma |
| US9944714B2 (en) | 2009-09-30 | 2018-04-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| WO2011041441A1 (fr) | 2009-09-30 | 2011-04-07 | Tracon Pharmaceuticals, Inc. | Anticorps anti-endogline |
| US9150652B2 (en) | 2009-09-30 | 2015-10-06 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| KR101398707B1 (ko) | 2009-09-30 | 2014-05-27 | 트라콘 파마수티칼즈, 인코포레이티드 | 엔도글린 항체 |
| US8609094B2 (en) | 2009-09-30 | 2013-12-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
| US20120269826A1 (en) | 2009-10-20 | 2012-10-25 | Mckee Charlotte | Anti-cd3 antibody dosing in autoimmune disease |
| WO2011050106A2 (fr) | 2009-10-20 | 2011-04-28 | Tolerx, Inc. | Dosage des anticorps anti-cd3 dans les maladies auto-immunes |
| US9695446B2 (en) | 2009-11-13 | 2017-07-04 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Direct protein delivery with engineered microvesicles |
| WO2011058052A1 (fr) | 2009-11-13 | 2011-05-19 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Administration directe de protéines à l'aide de microvésicules génétiquement modifiées |
| US8501180B2 (en) | 2010-01-15 | 2013-08-06 | Kyowa Hakko Kirin Co., Ltd | Anti system ASC amino acid transporter 2 (ASCT2) antibody |
| US8673592B2 (en) | 2010-01-15 | 2014-03-18 | Kyowa Hakko Kirin Co., Ltd | Anti system ASC amino acid transporter 2 (ASCT2) antibody |
| WO2011089211A1 (fr) | 2010-01-22 | 2011-07-28 | Synimmune Gmbh | Anticorps anti-cd133 et leurs procédés d'utilisation |
| US8911728B2 (en) | 2010-05-21 | 2014-12-16 | The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | High-affinity fully functional soluble single-domain human CD4, antibodies, and related fusion proteins |
| US9624303B2 (en) | 2010-05-26 | 2017-04-18 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-CD133 antibodies and uses thereof |
| US9249225B2 (en) | 2010-05-26 | 2016-02-02 | Regents Of The University Of Minnesota | Single chain variable fragment anti-CD133 antibodies and uses thereof |
| US20130224202A1 (en) | 2010-05-26 | 2013-08-29 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-cd133 antibodies and uses thereof |
| US11098109B2 (en) | 2010-05-26 | 2021-08-24 | Regents Of The University Of Minnesota | Single-chain variable fragment anti-CD133 antibodies and uses thereof |
| WO2011149493A1 (fr) | 2010-05-26 | 2011-12-01 | Regents Of The Unviversity Of Minnesota | Anticorps anti-cd133 à fragments monocaténaires variables et leurs utilisations |
| US9745552B2 (en) | 2010-12-02 | 2017-08-29 | Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. | Anti CD4 antibodies to prevent in particular graft-versus-host-disease (GvHD) |
| WO2012113348A1 (fr) | 2011-02-25 | 2012-08-30 | 厦门大学 | Anticorps monoclonal anti-protéine cd4, fragments actifs et utilisations de celui-ci |
| WO2012149412A2 (fr) | 2011-04-29 | 2012-11-01 | Immunogen Inc. | Anticorps anti-endogline (cd105), immunoconjugués et leurs utilisations |
| WO2012162067A2 (fr) | 2011-05-21 | 2012-11-29 | Macrogenics, Inc. | Molécules de liaison des cd3 capables de se lier aux cd3 humaines et non humaines |
| US9587021B2 (en) | 2011-05-21 | 2017-03-07 | Macrogenics, Inc. | CD3-binding molecules capable of binding to human and non-human CD3 |
| WO2012163805A1 (fr) | 2011-05-27 | 2012-12-06 | Glaxo Group Limited | Protéines de liaison à bcma (cd269/tnfrsf17) |
| US20200165336A1 (en) | 2011-06-06 | 2020-05-28 | Prothena Biosciences Limited | Mcam antagonists and methods of treatment |
| US20140314744A1 (en) | 2011-06-06 | 2014-10-23 | Neotope Biosciences Limited | Mcam antagonists and methods of treatment |
| WO2012170071A1 (fr) | 2011-06-06 | 2012-12-13 | Elan Pharmaceuticas, Inc | Antagonistes de mcam et méthodes de traitement |
| US10907177B2 (en) | 2011-09-30 | 2021-02-02 | Bluebird Bio, Inc. | Compounds for improved viral transduction |
| US20150073041A1 (en) | 2011-12-02 | 2015-03-12 | Yale University | Formulations for targeted release of agents to low ph tissue environments or cellular compartments and methods of use thereof |
| US20130172533A1 (en) | 2011-12-29 | 2013-07-04 | Industrial Technology Research Institute | Humanized anti-human cd34 monoclonal antibody and uses thereof |
| US8927696B2 (en) | 2011-12-29 | 2015-01-06 | Industrial Technology Research Institute | Humanized anti-human CD34 monoclonal antibody and uses thereof |
| WO2013148327A1 (fr) | 2012-03-26 | 2013-10-03 | The Regents Of The University Of California | Lentivirus pseudotypés avec l'enveloppe du virus nipah et méthodes d'utilisation |
| WO2013188870A2 (fr) | 2012-06-15 | 2013-12-19 | Beth Israel Deaconess Medical Center, Inc. | Anticorps iga cd4i et méthodes de traitement les utilisant |
| WO2014000338A1 (fr) | 2012-06-28 | 2014-01-03 | 中国科学院生物物理研究所 | Application d'un composite d'anticorps anti-cd146 et d'anticorps anti-vegf dans la préparation d'un médicament destiné à supprimer les tumeurs |
| WO2014025828A1 (fr) | 2012-08-06 | 2014-02-13 | The Regents Of The University Of California | Fragments d'anticorps recombinés par génie génétique pour le ciblage et l'imagerie de l'expression in vivo de cd8 |
| US20140093913A1 (en) | 2012-08-29 | 2014-04-03 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US20140080216A1 (en) | 2012-08-29 | 2014-03-20 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US10414825B2 (en) | 2012-09-10 | 2019-09-17 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
| US20180105602A1 (en) | 2012-09-10 | 2018-04-19 | Prothena Biosciences Limited | Anti-MCAM Antibodies And Associated Methods Of Use |
| US20140227292A1 (en) | 2012-09-10 | 2014-08-14 | Neotope Biosciences Limited | Anti-MCAM Antibodies And Associated Methods Of Use |
| US20170037144A1 (en) | 2012-09-10 | 2017-02-09 | Prothena Biosciences Limited | Anti-MCAM Antibodies And Associated Methods Of Use |
| US10584177B2 (en) | 2012-09-10 | 2020-03-10 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
| US10407507B2 (en) | 2012-09-10 | 2019-09-10 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
| US9447190B2 (en) | 2012-09-10 | 2016-09-20 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
| US20200216560A1 (en) | 2012-09-10 | 2020-07-09 | Prothena Biosciences Limited | Anti-MCAM Antibodies And Associated Methods Of Use |
| US20150239980A1 (en) | 2012-09-10 | 2015-08-27 | Neotope Bosciences Limited | Anti-mcam antibodies and associated methods of use |
| US9657102B2 (en) | 2012-09-21 | 2017-05-23 | Regeneron Pharmaceuticals, Inc. | Anti-CD3 antibodies, bispecific antigen-binding molecules that bind CD3 and CD20, and uses thereof |
| WO2014047231A1 (fr) | 2012-09-21 | 2014-03-27 | Regeneron Pharmaceuticals, Inc. | Anticorps anti-cd3, molécules de liaison à un antigène bispécifiques qui se lient à cd3 et cd20, et leurs utilisations |
| US20140242699A1 (en) | 2012-12-12 | 2014-08-28 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US20140170753A1 (en) | 2012-12-12 | 2014-06-19 | Massachusetts Institute Of Technology | Crispr-cas systems and methods for altering expression of gene products |
| US20140186919A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US20140273234A1 (en) | 2012-12-12 | 2014-09-18 | The Board Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US20140273232A1 (en) | 2012-12-12 | 2014-09-18 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| US20140310830A1 (en) | 2012-12-12 | 2014-10-16 | Feng Zhang | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US20150079681A1 (en) | 2012-12-12 | 2015-03-19 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US20140179006A1 (en) | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US20140242700A1 (en) | 2012-12-12 | 2014-08-28 | Massachusetts Institute Of Technology | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US20150184139A1 (en) | 2012-12-12 | 2015-07-02 | The Broad Institute Inc. | Crispr-cas systems and methods for altering expression of gene products |
| US20150203872A1 (en) | 2012-12-12 | 2015-07-23 | The Broad Institute Inc. | Crispr-cas systems and methods for altering expression of gene products |
| US20140256046A1 (en) | 2012-12-12 | 2014-09-11 | Massachusetts Institute Of Technology | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20150020223A1 (en) | 2012-12-12 | 2015-01-15 | The Broad Institute Inc. | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US20150232882A1 (en) | 2012-12-12 | 2015-08-20 | The Broad Institute Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| US20140242664A1 (en) | 2012-12-12 | 2014-08-28 | The Broad Institute, Inc. | Engineering of systems, methods and optimized guide compositions for sequence manipulation |
| US20140186843A1 (en) | 2012-12-12 | 2014-07-03 | Massachusetts Institute Of Technology | Methods, systems, and apparatus for identifying target sequences for cas enzymes or crispr-cas systems for target sequences and conveying results thereof |
| US20140273231A1 (en) | 2012-12-12 | 2014-09-18 | The Broad Institute, Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US20140248702A1 (en) | 2012-12-12 | 2014-09-04 | The Broad Institute, Inc. | CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US20140234972A1 (en) | 2012-12-12 | 2014-08-21 | Massachusetts Institute Of Technology | CRISPR-CAS Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes |
| US20150031134A1 (en) | 2012-12-12 | 2015-01-29 | The Broad Institute Inc. | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US20140179770A1 (en) | 2012-12-12 | 2014-06-26 | Massachusetts Institute Of Technology | Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications |
| US20140335620A1 (en) | 2012-12-12 | 2014-11-13 | The Broad Institute, Inc. | Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation |
| US20140227787A1 (en) | 2012-12-12 | 2014-08-14 | The Broad Institute, Inc. | Crispr-cas systems and methods for altering expression of gene products |
| US20140357530A1 (en) | 2012-12-12 | 2014-12-04 | The Broad Institute Inc. | Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof |
| US20140186958A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains |
| US20140189896A1 (en) | 2012-12-12 | 2014-07-03 | Feng Zhang | Crispr-cas component systems, methods and compositions for sequence manipulation |
| US9587022B2 (en) | 2012-12-18 | 2017-03-07 | The Rockefeller University | Glycan-modified anti-CD4 antibody with improved HIV-1 neutralizing activity |
| WO2014128185A1 (fr) | 2013-02-21 | 2014-08-28 | Universitätsklinikum Freiburg | Anticorps bispécifique de recombinaison se liant à l'antigène cd133 sur des cellules tumorales et au récepteur des lymphocytes t cd3 |
| US20200268850A1 (en) | 2013-02-28 | 2020-08-27 | President And Fellows Of Harvard College | Methods and compositions for mobilizing stem cells |
| WO2014164553A1 (fr) | 2013-03-13 | 2014-10-09 | Imaginab, Inc. | Constructions génétiques de liaison à l'antigène cd8 |
| US20150056705A1 (en) | 2013-05-15 | 2015-02-26 | Sangamo Biosciences, Inc. | Methods and compositions for treatment of a genetic condition |
| US20160194400A1 (en) | 2013-09-05 | 2016-07-07 | University Of Miyazaki | Antibody which specifically reacts with human integrin a6b4 |
| US10030071B2 (en) | 2013-09-05 | 2018-07-24 | University Of Miyazaki | Antibody which specifically reacts with human integrin A6B4 |
| WO2015034052A1 (fr) | 2013-09-05 | 2015-03-12 | 国立大学法人 宮崎大学 | Anticorps qui réagit spécifiquement avec l'intégrine humaine a6b4 |
| US20160206764A1 (en) | 2013-09-24 | 2016-07-21 | Oncoinvent As | Monoclonal antibody and derivatives |
| US9782500B2 (en) | 2013-09-24 | 2017-10-10 | Oncoinvent As | Monoclonal antibody and derivatives |
| WO2015044218A1 (fr) | 2013-09-24 | 2015-04-02 | Oncoinvent As | Anticorps monoclonaux et dérivés |
| US20160280789A1 (en) | 2013-11-08 | 2016-09-29 | Children's Hospital Los Angeles | Methods for treating hematological malignancies |
| WO2015118031A2 (fr) | 2014-02-06 | 2015-08-13 | Oncomatryx Biopharma, S.L. | Conjugués anticorps-médicament et immunotoxines |
| US20170007714A1 (en) | 2014-02-06 | 2017-01-12 | Oncomatryx Biopharma, S.L. | Antibody-drug conjugates and immunotoxins |
| US11214628B2 (en) | 2014-02-12 | 2022-01-04 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| WO2015121383A1 (fr) | 2014-02-12 | 2015-08-20 | Michael Uhlin | Anticorps bispécifiques utilisables dans une transplantation de cellules souches |
| US20170298148A1 (en) | 2014-02-12 | 2017-10-19 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US20190135945A1 (en) | 2014-02-12 | 2019-05-09 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US10106623B2 (en) | 2014-02-12 | 2018-10-23 | Michael Uhlin | Bispecific antibodies for use in stem cell transplantation |
| US20170002089A1 (en) | 2014-03-12 | 2017-01-05 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| US20170101470A1 (en) | 2014-03-12 | 2017-04-13 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| US20170129954A1 (en) | 2014-03-12 | 2017-05-11 | Prothena Biosciences Limited | Use of Anti-MCAM Antibodies for Treatment or Prophylaxis of Giant Cell Arteritis, Polymyalgia Rheumatica or Takayasus Arteritis |
| WO2015136469A1 (fr) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anticorps anti-mcam et procédés d'utilisation associés |
| US10407506B2 (en) | 2014-03-12 | 2019-09-10 | Prothena Biosciences Limited | Anti-MCAM antibodies and associated methods of use |
| WO2015136470A1 (fr) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anticorps anti-mcam et procédés d'utilisation associés |
| US20150259419A1 (en) | 2014-03-12 | 2015-09-17 | Prothena Biosciences Limited | Anti-MCAM Antibodies and Associated Methods of Use |
| US20200010563A1 (en) | 2014-03-12 | 2020-01-09 | Prothena Biosciences Limited | Anti-mcam antibodies and associated methods of use |
| WO2015161276A2 (fr) | 2014-04-18 | 2015-10-22 | Editas Medicine, Inc. | Méthodes, compositions et constituants associés à crispr/cas pour l'immunothérapie du cancer |
| US20170106021A1 (en) | 2014-05-12 | 2017-04-20 | The General Hospital Corporation | Compositions enriched for hox11+ stem cells and methods of preparing the same |
| US10704061B2 (en) | 2014-05-21 | 2020-07-07 | Ip2Ipo Innovations Limited | Lentiviral vectors |
| WO2015184203A1 (fr) | 2014-05-29 | 2015-12-03 | Macrogenics, Inc. | Molécules de liaison trispécifiques et leurs procédés d'utilisation |
| US10106609B2 (en) | 2014-06-04 | 2018-10-23 | PeronGen BioTherapeutics (Suzhou) Co., Ltd. | CD7 nanobodies, encoding sequence and use thereof |
| WO2015184941A1 (fr) | 2014-06-04 | 2015-12-10 | 博生吉医药科技(苏州)有限公司 | Nanocorps de cd7, séquence codante et son utilisation |
| US10336831B2 (en) | 2014-11-12 | 2019-07-02 | Tracon Pharmaceuticals, Inc. | Use of anti-endoglin antibodies for treating ocular fibrosis |
| US9926375B2 (en) | 2014-11-12 | 2018-03-27 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| WO2016077451A1 (fr) | 2014-11-12 | 2016-05-19 | Tracon Pharmaceuticals, Inc. | Anticorps anti-endogline et leurs utilisations |
| US10155820B2 (en) | 2014-11-12 | 2018-12-18 | Tracon Pharmaceuticals, Inc. | Anti-endoglin antibodies and uses thereof |
| US20160176969A1 (en) | 2014-11-26 | 2016-06-23 | Xencor, Inc. | Heterodimeric antibodies including binding to cd8 |
| US20180057597A1 (en) | 2015-01-23 | 2018-03-01 | Sanofi | Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123 |
| WO2016116626A1 (fr) | 2015-01-23 | 2016-07-28 | Sanofi | Anticorps anti-cd3, anticorps anti-cd123 et anticorps bispécifiques se liant spécifiquement à cd3 et/ou cd123 |
| WO2016154623A2 (fr) | 2015-03-26 | 2016-09-29 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Anticorps monoclonaux anti-cd133 et compositions et méthodes associées |
| US11352435B2 (en) | 2015-03-26 | 2022-06-07 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD133 monoclonal antibodies and related compositions and methods |
| US10711068B2 (en) | 2015-03-26 | 2020-07-14 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Anti-CD133 monoclonal antibodies and related compositions and methods |
| WO2016180721A1 (fr) | 2015-05-08 | 2016-11-17 | Miltenyi Biotec Gmbh | Anticorps humanisé ou fragment de celui-ci spécifique pour cd3 |
| US20180112000A1 (en) | 2015-05-08 | 2018-04-26 | Miltenyi Biotec Gmbh | Humanized antibody or fragment thereof specific for cd3 |
| US20200100838A1 (en) | 2015-05-12 | 2020-04-02 | National University Of Ireland, Galway | Devices for therapeutic nasal neuromodulation and associated methods and systems |
| WO2016204966A1 (fr) | 2015-06-16 | 2016-12-22 | Genentech, Inc. | Anticorps anti-cd3 et leurs méthodes d'utilisation |
| US11007267B2 (en) | 2015-06-16 | 2021-05-18 | Genentech, Inc. | Anti-CD3 antibodies and methods of use |
| WO2018028647A1 (fr) | 2015-08-11 | 2018-02-15 | Legend Biotech Usa Inc. | Récepteurs d'antigène chimériques ciblant bcma et leurs procédés d'utilisation |
| US20180169177A1 (en) | 2015-08-18 | 2018-06-21 | Guangzhou Yidai Pharmaceutical Co., Ltd. | Polypeptide specifically binding to cd34 molecule and use thereof |
| WO2017046776A2 (fr) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de l'artérite à cellules géantes, la pseudo-polyarthrite rhizomélique ou l'artérite de takayasu |
| WO2017046774A2 (fr) | 2015-09-16 | 2017-03-23 | Prothena Biosciences Limited | Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de l'artérite à cellules géantes, la pseudo-polyarthrite rhizomélique ou l'artérite de takayasu |
| WO2017068077A1 (fr) | 2015-10-20 | 2017-04-27 | Institut National De La Sante Et De La Recherche Medicale (Inserm) | Méthodes et produits pour génie génétique |
| US20170112773A1 (en) | 2015-10-23 | 2017-04-27 | Board Of Regents, The University Of Texas System | Plasma membrane vesicles comprising functional transmembrane proteins |
| US20180273617A1 (en) | 2015-11-10 | 2018-09-27 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| US20210024629A1 (en) | 2015-11-10 | 2021-01-28 | Medimmune, Llc | Binding molecules specific for asct2 and uses thereof |
| WO2017083451A1 (fr) | 2015-11-10 | 2017-05-18 | Medimmune, Llc | Molécules de liaison spécifiques d'asct2 et leurs utilisations |
| US10829554B2 (en) | 2015-11-10 | 2020-11-10 | Medimmune, Llc | Binding molecules specific for ASCT2 and uses thereof |
| WO2017095944A1 (fr) | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Procédés et compositions se rapportant à des chondrisomes provenant de produits sanguins |
| WO2017095940A1 (fr) | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Procédés et compositions se rapportant à des chondrisomes provenant de cellules cultivées |
| WO2017095946A1 (fr) | 2015-11-30 | 2017-06-08 | Flagship Pioneering, Inc. | Procédés et compositions se rapportant aux chondrisomes |
| WO2017093969A1 (fr) | 2015-12-04 | 2017-06-08 | Novartis Ag | Compositions et procédés d'immuno-oncologie |
| US10316295B2 (en) | 2015-12-17 | 2019-06-11 | The Penn State Research Foundation | Paramyxovirus virus-like particles as protein delivery vehicles |
| WO2017104735A1 (fr) | 2015-12-18 | 2017-06-22 | 富士フイルム株式会社 | Composition absorbant dans le proche infrarouge, filtre de coupure du proche infrarouge, procédé de fabrication de filtre de coupure du proche infrarouge, élément d'imagerie à semi-conducteurs, module d'appareil de prise de vues, et dispositif d'affichage d'image |
| WO2017134306A1 (fr) | 2016-02-05 | 2017-08-10 | Orionis Biosciences Nv | Agents de liaison au cd8 |
| WO2017149513A1 (fr) | 2016-03-03 | 2017-09-08 | Prothena Biosciences Limited | Anticorps anti-mcam et méthodes d'utilisation associées |
| WO2017153953A1 (fr) | 2016-03-09 | 2017-09-14 | Prothena Biosciences Limited | Utilisation d'anticorps anti-mcam pour le traitement ou la prophylaxie de maladies pulmonaires granulomateuses |
| US20190144885A1 (en) | 2016-04-21 | 2019-05-16 | Ecole Normale Superieure De Lyon | Methods for selectively modulating the activity of distinct subtypes of cells |
| WO2017182585A1 (fr) | 2016-04-21 | 2017-10-26 | Ecole Normale Superieure De Lyon | Procédés de modulation de manière sélective de l'activité de sous-types distincts de cellules |
| WO2017193107A2 (fr) | 2016-05-06 | 2017-11-09 | Juno Therapeutics, Inc. | Cellules génétiquement modifiées et leurs procédés de fabrication |
| US20170320966A1 (en) | 2016-05-09 | 2017-11-09 | Industrial Technology Research Institute | Humanized monoclonal antibody and uses thereof |
| WO2017208210A1 (fr) | 2016-06-03 | 2017-12-07 | Prothena Biosciences Limited | Anticorps anti-mcam et methodes d'utilisation associées |
| WO2017213979A1 (fr) | 2016-06-06 | 2017-12-14 | St. Jude Children's Research Hospital | Récepteur d'antigène chimérique anti-cd7 et son procédé d'utilisation |
| US20210054068A1 (en) | 2016-06-08 | 2021-02-25 | The Board Of Trustees Of The Leland Stanford Junior University | Detection of pancreatic cancer with an engineered anti-thy1 single-chain antibody |
| WO2018035001A1 (fr) | 2016-08-13 | 2018-02-22 | United Biomedical, Inc. | Traitement et rémission virologique prolongée d'une infection par le vih à l'aide d'anticorps dirigés contre les cd4 chez des patients stabilisés suite à un traitement haart |
| WO2018033630A1 (fr) | 2016-08-19 | 2018-02-22 | Oncoinvent As | Récepteur antigénique chimérique (car) anti-ostéosarcome-t dérivé de l'anticorps oi-3 |
| US20190192573A1 (en) | 2016-08-19 | 2019-06-27 | Oncoinvent As | Anti-osteosarcoma car-t derived from the antibody oi-3 |
| WO2018045880A1 (fr) | 2016-09-06 | 2018-03-15 | Guangzhou Bainifu Biotech Co., Ltd | Récepteur d'antigène chimère, cellules car133-nkt et leur utilisation |
| WO2018067819A1 (fr) | 2016-10-06 | 2018-04-12 | Tracon Pharmaceuticals, Inc. | Compositions et méthodes de traitement de cancers |
| US11220551B2 (en) | 2016-10-19 | 2022-01-11 | The Governing Council Of The University Of Toronto | CD133-binding agents and uses thereof |
| CA2962157A1 (fr) | 2016-10-19 | 2018-04-19 | The Governing Council Of The University Of Toronto | Agents de liaison cd133 et utilisations associees |
| WO2018072025A1 (fr) | 2016-10-19 | 2018-04-26 | The Governing Council Of The University Of Toronto | Agents de liaison à cd133 et leurs utilisations |
| WO2018089393A1 (fr) | 2016-11-10 | 2018-05-17 | Medimmune, Llc | Molécules de liaison spécifiques d'asct2 et leurs utilisations |
| US20190367605A1 (en) | 2016-11-10 | 2019-12-05 | Medimmune, Llc | Binding Molecules Specific For ASCT2 And Uses Thereof |
| WO2018098306A1 (fr) | 2016-11-22 | 2018-05-31 | National University Of Singapore | Blocage de l'expression de cd7 et récepteurs d'antigènes chimériques pour l'immunothérapie de malignités de lymphocytes t |
| WO2018127655A1 (fr) | 2017-01-04 | 2018-07-12 | Moduleus | Circuit de commande de transducteurs ultrasonores |
| WO2018170096A1 (fr) | 2017-03-14 | 2018-09-20 | Dualogics, Llc | Utilisation d'un anticorps bispécifique anti-cd4/cd8 pour le traitement du diabète |
| WO2018208728A1 (fr) | 2017-05-08 | 2018-11-15 | Flagship Pioneering, Inc. | Compositions pour faciliter la fusion membranaire et leurs utilisations |
| WO2018213337A1 (fr) | 2017-05-15 | 2018-11-22 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Récepteurs d'antigènes chimériques bicistroniques et leurs utilisations |
| WO2018220467A1 (fr) | 2017-05-30 | 2018-12-06 | Foroogh Nejatollahi | Immunotoxine humaine anti-muc18 et ses applications |
| US10905771B2 (en) | 2017-05-30 | 2021-02-02 | Foroogh Nejatollahi | Anti-MUC18 human immunotoxin and applications thereof |
| US20180271994A1 (en) | 2017-05-30 | 2018-09-27 | Foroogh Nejatollahi | Anti-muc18 human immunotoxin and applications thereof |
| WO2018223140A1 (fr) | 2017-06-02 | 2018-12-06 | Prothena Biosciences Limited | Anticorps anti-mcam et methodes d'utilisation associées |
| US20210093667A1 (en) | 2017-06-26 | 2021-04-01 | The Broad Institute, Inc. | Crispr/cas-adenine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
| US20200248169A1 (en) | 2017-06-26 | 2020-08-06 | The Broad Institute, Inc. | Crispr/cas-cytidine deaminase based compositions, systems, and methods for targeted nucleic acid editing |
| WO2019006072A1 (fr) | 2017-06-30 | 2019-01-03 | The United States Of America, As Represented By The Secretary, Department Of Health And Human Services | Récepteurs antigéniques chimériques vers l'antigène de maturation des lymphocytes b présentant des domaines humains |
| US10730944B2 (en) | 2017-07-24 | 2020-08-04 | Regeneron Pharmaceuticals, Inc. | Anti-CD8 antibodies and uses thereof |
| WO2019032661A1 (fr) | 2017-08-09 | 2019-02-14 | Orionis Biosciences Inc. | Agents de liaison au cd8 |
| US20200172620A1 (en) | 2017-08-11 | 2020-06-04 | Genentech, Inc. | Anti-cd8 antibodies and uses thereof |
| WO2019068842A1 (fr) | 2017-10-06 | 2019-04-11 | Universite D'aix-Marseille | Anticorps anti-cd146 et leurs utilisations |
| US11427648B2 (en) | 2017-10-06 | 2022-08-30 | Universite D'aix-Marseille | Anti-CD146 antibodies and uses thereof |
| US20200262929A1 (en) | 2017-10-06 | 2020-08-20 | Universite D'aix-Marseille | Anti-cd146 antibodies and uses thereof |
| WO2019086534A1 (fr) | 2017-10-31 | 2019-05-09 | Xenikos Bv | Immunotoxines, formulations associées et leurs utilisations en médecine |
| US11447548B2 (en) | 2017-10-31 | 2022-09-20 | Xenikos B.V. | Immunotoxins, formulations thereof and their use in medicine |
| WO2019102234A1 (fr) | 2017-11-27 | 2019-05-31 | Bivictrix Therapeutics Limited | Traitement combiné anti-cd33 et anti-cd7 |
| WO2019113512A1 (fr) | 2017-12-07 | 2019-06-13 | Flagship Pioneering Innovations V, Inc. | Produits cytobiologiques et leurs utilisations thérapeutiques |
| WO2019126709A1 (fr) | 2017-12-22 | 2019-06-27 | The Broad Institute, Inc. | Systèmes cas12b, procédés et compositions pour l'édition de base d'adn ciblée |
| US20210071163A1 (en) | 2017-12-22 | 2021-03-11 | The Broad Institute, Inc. | Cas12b systems, methods, and compositions for targeted rna base editing |
| US20210079366A1 (en) | 2017-12-22 | 2021-03-18 | The Broad Institute, Inc. | Cas12a systems, methods, and compositions for targeted rna base editing |
| WO2019133639A2 (fr) | 2017-12-26 | 2019-07-04 | The Regents Of The University Of California | Anticorps humains qui se lient et sont assimilés par des cellules de mésothéliome et autres cellules cancéreuses |
| WO2019137309A1 (fr) | 2018-01-09 | 2019-07-18 | 南京任诺药业有限公司 | Anticorps monoclonal anti-cd146 humain humanisé ayant une activité de neutralisation élevée |
| US20200246381A1 (en) | 2018-02-01 | 2020-08-06 | Nanjing Iaso Biotherapeutics Co., Ltd. | Chimeric antigen receptor (car) binding to bcma, and uses thereof |
| US20200339699A1 (en) | 2018-02-01 | 2020-10-29 | Innovent Biologics (Suzhou) Co., Ltd. | Fully humanized anti-b cell maturation antigen (bcma) single-chain antibody and use thereof |
| US11026975B2 (en) | 2018-02-01 | 2021-06-08 | Nanjing Iaso Biotherapeutics Co., Ltd. | Chimeric antigen receptor (CAR) binding to BCMA, and uses thereof |
| WO2019157319A1 (fr) | 2018-02-12 | 2019-08-15 | Flagship Pioneering Innovations V, Inc. | Dispositifs et procédés pour administrer une matière dans un tissu biologique ou une cellule |
| WO2019161281A1 (fr) | 2018-02-17 | 2019-08-22 | Flagship Pioneering Innovations V, Inc. | Compositions et procédés d'administration de protéines membranaires |
| WO2019203497A1 (fr) | 2018-04-17 | 2019-10-24 | 국립암센터 | Composition d'assistance de produit de thérapie anticancéreuse par lymphocytes t comprenant un anticorps monoclonal anti-cd4 induisant la déplétion des lymphocytes cd4+ et son utilisation |
| WO2019222403A2 (fr) | 2018-05-15 | 2019-11-21 | Flagship Pioneering Innovations V, Inc. | Compositions de fusosome et leurs utilisations |
| WO2019236684A1 (fr) | 2018-06-08 | 2019-12-12 | Imaginab, Inc. | Constructions de liaison d'antigène à cd4 |
| WO2020014209A1 (fr) | 2018-07-09 | 2020-01-16 | Flagship Pioneering Innovations V, Inc. | Compositions de fusosomes et utilisations associées |
| WO2020051277A1 (fr) | 2018-09-06 | 2020-03-12 | Board Of Regents, The University Of Texas System | Traitement et prévention de l'arthropathie hémophilique avec un anticorps contre le récepteur cellulaire endothélial de la protéine c (epcr) |
| US20210355231A1 (en) | 2018-09-06 | 2021-11-18 | Board Of Regents, The University Of Texas System | Treatment and prevention of hemophilic arthropathy with an antibody against endothelial cell protein c receptor (epcr) |
| US20220127622A1 (en) | 2018-09-07 | 2022-04-28 | Beam Therapeutics Inc. | Compositions and Methods for Improving Base Editing |
| WO2020060924A1 (fr) | 2018-09-17 | 2020-03-26 | Dualogics, Llc | Utilisation d'un anticorps bispécifique cd4/cd8 pour le traitement de troubles auto-immuns/inflammatoires |
| WO2020069433A1 (fr) | 2018-09-28 | 2020-04-02 | Imaginab, Inc. | Constructions d'imagerie de cd8 et leurs méthodes d'utilisation |
| WO2020102503A2 (fr) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Compositions de fusosome pour administration à des lymphocytes t |
| WO2020102578A1 (fr) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc | Compositions et procédés de livraison de cargaison à compartiment spécifique |
| WO2020102499A2 (fr) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Compositions à base de fusosomes pour l'administration de snc |
| WO2020102485A1 (fr) | 2018-11-14 | 2020-05-22 | Flagship Pioneering Innovations V, Inc. | Compositions de fusosomes pour l'apport de cellules souches hématopoïétiques |
| WO2020132232A2 (fr) | 2018-12-21 | 2020-06-25 | Multitude Inc. | Anticorps spécifiques à muc18 |
| WO2020132190A1 (fr) | 2018-12-21 | 2020-06-25 | Multitude Inc. | Anticorps spécifiques à muc18 |
| US20220041748A1 (en) | 2018-12-21 | 2022-02-10 | Multitude Inc. | Antibodies specific to muc18 |
| US20220041749A1 (en) | 2018-12-21 | 2022-02-10 | Multitude Inc. | Antibodies specific to muc18 |
| US20220127374A1 (en) | 2019-02-06 | 2022-04-28 | Nottingham Trent University | ANTIBODIES AGAINST hEPCR |
| WO2020161478A1 (fr) | 2019-02-06 | 2020-08-13 | Nottingham Trent University | Anticorps dirigés contre le hepcr |
| WO2020181202A1 (fr) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | Édition de base a:t en t:a par déamination et oxydation d'adénine |
| WO2020181193A1 (fr) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | Édition de bases t:a à a:t par méthylation de l'adénosine |
| WO2020181178A1 (fr) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | Édition de base t:a à a:t par alkylation de thymine |
| WO2020181195A1 (fr) | 2019-03-06 | 2020-09-10 | The Broad Institute, Inc. | Édition de base t : a à a : t par excision d'adénine |
| WO2020191248A1 (fr) | 2019-03-19 | 2020-09-24 | The Broad Institute, Inc. | Procédés et compositions pour l'édition de séquences nucléotidiques |
| WO2020214842A1 (fr) | 2019-04-17 | 2020-10-22 | The Broad Institute, Inc. | Éditeurs de base d'adénine présentant des effets hors cible réduits |
| WO2020212710A1 (fr) | 2019-04-18 | 2020-10-22 | Kymab Limited | Anticorps anti-cd7 antagonistes |
| WO2020228824A1 (fr) | 2019-05-16 | 2020-11-19 | Nanjing Legend Biotech Co., Ltd. | Récepteurs de cellules immunitaires comprenant des fractions de liaison à cd4 |
| WO2020257412A1 (fr) | 2019-06-19 | 2020-12-24 | Orionis Biosciences, Inc. | Polythérapie avec des protéines chimériques ou des complexes protéiques chimériques ciblant cd13 |
| WO2021076788A2 (fr) | 2019-10-16 | 2021-04-22 | Umoja Biopharma, Inc. | Vecteur rétroviral pour thérapie du récepteur universel |
| WO2021118955A1 (fr) | 2019-12-13 | 2021-06-17 | Aggamin Llc | Méthodes et systèmes de traitement ou de prévention de troubles de l'hypertension liés à la grossesse |
| WO2021118957A1 (fr) | 2019-12-13 | 2021-06-17 | Aggamin Llc | Méthodes et systèmes de traitement ou de prévention de troubles d'hypertension liés à la grossesse |
| WO2021158921A2 (fr) | 2020-02-05 | 2021-08-12 | The Broad Institute, Inc. | Éditeurs de base d'adénine et leurs utilisations |
| WO2021160267A1 (fr) | 2020-02-13 | 2021-08-19 | UCB Biopharma SRL | Anticorps bispécifiques dirigés contre cd9 et cd7 |
| WO2021211450A1 (fr) | 2020-04-13 | 2021-10-21 | Fred Hutchinson Cancer Research Center | Régimes de conditionnement pour thérapie génique in vivo |
| WO2021226558A1 (fr) | 2020-05-08 | 2021-11-11 | The Broad Institute, Inc. | Méthodes et compositions d'édition simultanée des deux brins d'une séquence nucléotidique double brin cible |
| WO2022022718A1 (fr) | 2020-07-31 | 2022-02-03 | 北京市神经外科研究所 | Anticorps à chaîne unique anti-cd133 et son utilisation dans la préparation d'un médicament pour le traitement d'une tumeur |
| EP3964585A1 (fr)* | 2020-09-03 | 2022-03-09 | Miltenyi Biotec B.V. & Co. KG | Particule de vecteur lentiviral spécifique de cd62l pour la transduction ciblée de sous-ensembles de lymphocytes t |
| WO2022067130A2 (fr) | 2020-09-24 | 2022-03-31 | The Broad Institute, Inc. | Arn guides d'édition primaire, leurs compositions et leurs méthodes d'utilisation |
| WO2022082073A2 (fr) | 2020-10-16 | 2022-04-21 | Board Of Regents, The University Of Texas System | Compositions et méthodes de ciblage de muc18 |
| WO2022095803A1 (fr) | 2020-11-03 | 2022-05-12 | 南京北恒生物科技有限公司 | Anticorps humanisé ciblant cd7 et son utilisation |
| WO2022136887A1 (fr) | 2020-12-23 | 2022-06-30 | Bivictrix Limited | Nouveaux procédés de thérapie |
| WO2022136888A1 (fr) | 2020-12-23 | 2022-06-30 | Bivictrix Limited | Anticorps bispécifiques se liant à cd7 et cd33 |
| WO2022151851A1 (fr) | 2021-01-12 | 2022-07-21 | 上海雅科生物科技有限公司 | Cellule immunitaire génétiquement modifiée ciblant cd7, récepteur antigénique chimérique, molécule de blocage de cd7 et utilisation associée |
| US20220233591A1 (en) | 2021-01-25 | 2022-07-28 | Beijing Daxi Biotechnology Co., Ltd | Preparation method of nk cells and use thereof in the treatment of cancer |
| WO2022164935A1 (fr) | 2021-01-27 | 2022-08-04 | Umoja Biopharma, Inc. | Lentivirus permettant de générer des cellules exprimant un récepteur antigénique chimérique anti-cd19 |
| WO2022216915A1 (fr)* | 2021-04-08 | 2022-10-13 | Sana Biotechnology, Inc. | Constructions d'anticorps spécifiques de cd8 et compositions associées |
| US11535869B2 (en) | 2021-04-08 | 2022-12-27 | Sana Biotechnology, Inc. | CD8-specific antibody constructs and compositions thereof |